1. Health Canada. Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs) (publication 2010/03/05) (Health Canada Publications, 2010).
2. EMEA. Comparability of biotechnological/biological products subject to changes in their manufacturing process (CPMP/ICH/5721/03) (European Medicines Agency, 2006).
3. US Food and Drug Administration. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product (UCM291134) (US FDA Office of Communications, 2012).
4. US FDA. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product (UCM291128) (US FDA Office of Communications, 2012).
5. Gabrielson, J.P. & Weiss, W.F. 4th. J. Pharm. Sci. 104, 1240–1245 (2015).